Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda Reports Better Version Of Prevacid Heartburn Drug

This article was originally published in PharmAsia News

Executive Summary

In a comparison with its best-selling drug Prevacid (lansoprazole), Takeda Pharmaceutical says its new version of the heartburn drug, TAK-390MR, has proven to be more effective. Takeda said a pair of Phase III trials of patients with erosive esophagitis showed the newer version to be better. The results are important to Takeda since Prevacid is set to lose patent protection in November of next year. Takeda hopes to introduce the new version by the end of this year. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts